Blue Arbor Technologies
Implantable neuromuscular interface system for intuitive control of upper-limb prostheses.
Website: https://bluearbortech.com/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | Blue Arbor Technologies |
| Tagline | Implantable neuromuscular interface system for intuitive control of upper-limb prostheses. |
| Headquarters | Ann Arbor, US |
| Founded | 2015 |
| Stage | Series A |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+) |
| Funding label | Series A |
| Total disclosed | ~$15,500,000 [Blue Arbor Technologies, February 2026] [Business Wire, October 2026] |
Links
Public sources
- Website: https://bluearbortech.com/
Executive Summary
PUBLIC Blue Arbor Technologies is developing an implantable neuromuscular interface system for upper-limb prostheses, and it merits investor attention now because the company has paired early regulatory validation with fresh strategic funding from Ottobock, a major prosthetics incumbent [Blue Arbor Technologies, April 2024] [Business Wire, October 2026]. Founded in 2015 and based in Ann Arbor, Blue Arbor appears to be commercializing science that originated in long-running academic and clinical research, with public coverage tying the company to University of Michigan roots and a translational path that has been underway for years [Crain’s Detroit Business, October 2026] [Behind the Microscope, February 2022].
The core product, RESTORE, is designed to connect a patient’s peripheral nervous system to a robotic upper-extremity prosthesis, with the stated aim of enabling more intuitive and simultaneous control than external surface-signal approaches have historically allowed [BioSpace, April 2024] [Medical Design & Outsourcing, June 2024]. That differentiation matters if it holds up clinically, because Blue Arbor is not trying to build the prosthetic limb itself, it is trying to become the control layer that improves performance of commercially available robotic arms and hands [Medical Design & Outsourcing, June 2024] [Docwire News, February 2026].
The founding team is unusually research-heavy for a device startup at this stage. Public materials identify Dr. Paul Cederna as President, Dr. Theodore Kung as Chief Medical Officer, and Dr. Alex Vaskov as Chief Technology Officer, while third-party coverage attributes more than $60 million in collective direct research grant funding to the founders and more than 200 peer-reviewed publications to their work [ODT, February 2026] [Today’s Medical Developments, February 2026] [Pulse2, February 2026].
On capital formation, the public record shows a February 2026 $5 million Series A investment from Ottobock and an October 2026 announcement of a $10.5 million Series A led by Ottobock, for roughly $15.5 million in disclosed financing, although third-party databases are not fully consistent on cumulative totals [Blue Arbor Technologies, February 2026] [Business Wire, October 2026] [PitchBook]. The business model reads as hardware plus software in a regulated medtech stack, with commercialization likely tied to clinical validation, regulatory progress, and strategic channel alignment with prosthetics ecosystem partners rather than a pure direct-to-consumer motion [Medical Design & Outsourcing, June 2024] [EQS News, February 2026].
Over the next 12 to 18 months, the key items to watch are progression from first and second human implantations into broader U.S. clinical work, evidence that the FDA Breakthrough Device and TAP designations translate into an executable IDE pathway, and signs that Ottobock’s role expands from investor to meaningful commercial partner [Blue Arbor Technologies, April 2024] [Medical Design & Outsourcing, February 2026] [ODT, October 2026]. The company has a credible scientific base and a strategically relevant backer; the remaining question is whether that foundation converts into repeatable clinical outcomes and a viable adoption path in upper-limb prosthetics.
Lightly corroborated -- This section relies on a mix of company releases and independent trade and business press, with core funding and FDA claims corroborated by multiple public sources but several product and clinical-development details still resting on limited third-party verification.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Disclosed funding of approximately $15.5 million |
How the Company Got Here
PUBLIC
Blue Arbor Technologies is an Ann Arbor, Michigan company developing neuromuscular interface technology for people with upper-limb loss [Blue Arbor Technologies]. The public record here is still relatively lean, but the dated milestones are clear enough to frame the business: the company was founded in 2015, and its current website describes a focus on prosthetic control systems rather than prosthetic-limb manufacturing itself [Blue Arbor Technologies].
The chronology matters because most of Blue Arbor's externally visible progress has clustered in the last two years. In April 2024, the company announced that its RESTORE Neuromuscular Interface System received FDA Breakthrough Device Designation and was enrolled in the FDA's Total Product Life Cycle Advisory Program pilot, a meaningful regulatory marker for a device company still moving toward broader clinical development [Blue Arbor Technologies, April 2024]. In February 2026, Blue Arbor disclosed a strategic partnership with Ottobock alongside a $5 million Series A investment, and in October 2026 it announced a further $10.5 million Series A financing led by Ottobock, bringing disclosed funding to about $15.5 million across the two announcements [Blue Arbor Technologies, February 2026] [Business Wire, October 2026].
That sequence suggests a company transitioning from research-heavy development into a more formal commercialization and clinical-preparation phase, with a strategic investor that is directly relevant to the prosthetics ecosystem [Blue Arbor Technologies, February 2026] [Business Wire, October 2026]. The same public materials identify three co-founders, Dr. Paul Cederna, Dr. Theodore Kung, and Dr. Alex Vaskov, and position the company around a platform intended to connect neuromuscular signals to advanced upper-limb prostheses [Blue Arbor Technologies, February 2026].
Lightly corroborated -- Grounded primarily in Blue Arbor's website and press materials, with partial corroboration from Business Wire for the October 2026 financing.
Product and Technology
Sources and analysis
Blue Arbor is building around a specific control problem in upper-limb prosthetics, not around the prosthetic limb itself. Public materials describe the RESTORE Neuromuscular Interface System as a system that connects a patient’s peripheral nervous system to a robotic upper-extremity prosthesis, with the stated goal of making control more intuitive and allowing more independent, simultaneous movement across the fingers, wrist, and elbow [BioSpace, April 2024] [Medical Design & Outsourcing, June 2024]. That distinction matters because the commercial claim is narrower than a full-stack prosthetics platform: Blue Arbor is positioning RESTORE as the interface layer between biological signals and commercially available robotic prosthetics [Docwire News, February 2026] [Medical Design & Outsourcing, June 2024].
The underlying architecture is presented as implant-based. Blue Arbor and related coverage describe implanted or intramuscular electrodes, plus a sensing and signal-translation system that converts neuromuscular signals into control commands for the prosthesis [Medical Design & Outsourcing, June 2024] [EQS News, February 2026]. The most credible public validation point so far is regulatory rather than commercial: the U.S. Food and Drug Administration granted Breakthrough Device Designation to RESTORE in April 2024, and Blue Arbor said the device was also enrolled in the FDA Total Product Life Cycle Advisory Program pilot at that time [Blue Arbor Technologies, April 2024] [BioSpace, April 2024]. By February 2026, the company and trade coverage also reported a first human implantation at the Medical University of Vienna, with October 2026 coverage indicating two human implantations had been completed [Blue Arbor Technologies, February 2026] [Medical Design & Outsourcing, February 2026] [ODT, October 2026].
What remains less settled in the public record is performance at scale. The available sources support that Blue Arbor has moved from preclinical science into early human use and FDA engagement, but they do not provide published efficacy outcomes, durability data, or evidence yet of routine deployment with prosthetics providers [Blue Arbor Technologies, February 2026] [Business Wire, October 2026]. For investors, the technical bet is therefore legible: if implanted sensing materially improves control fidelity over external signal capture, Blue Arbor could occupy a valuable enabling layer in advanced prosthetics, but the evidence in public today is still early-stage and mostly milestone-based rather than outcomes-based [Medical Design & Outsourcing, June 2024] [Business Wire, October 2026].
Lightly corroborated -- Product positioning is corroborated across company, trade, and republished press coverage, but several device-detail and human-use claims still rely partly on company-originated disclosures.
Where the Demand Sits
Public sources
This market matters now because Blue Arbor is trying to sit at the intersection of two slow-moving but newly converging systems, advanced upper-limb prosthetics and implantable neurotechnology, and the pace of adoption will depend as much on clinical workflow and reimbursement as on signal quality itself [Medical Design & Outsourcing, June 2024] [BioSpace, April 2024].
The public record does not provide a clean TAM, SAM, or SOM for Blue Arbor’s specific category, which is intuitive control systems for upper-limb prostheses. What is visible is narrower and more useful: Blue Arbor is not positioning itself as a prosthetic-limb manufacturer, but as a control layer intended to work with commercially available robotic prosthetics [Medical Design & Outsourcing, June 2024] [Docwire News, February 2026]. That places it inside an analogous market composed of upper-limb prosthetic components, prosthetic clinics, and neurotech-enabled rehabilitation devices, rather than the full orthopedics or medtech market. For investors, that distinction matters because a control-system company can scale through partnerships with incumbent prosthetic manufacturers and providers if clinical data support better functional outcomes [Blue Arbor Technologies, February 2026] [Business Wire, October 2026].
Demand drivers are visible even without a formal market-size report. The company and its coverage repeatedly frame the product around a specific unmet need: more intuitive, simultaneous control of fingers, wrist, and elbow for people with upper-limb loss, which conventional surface-electrode approaches have struggled to deliver consistently according to trade coverage [Medical Design & Outsourcing, June 2024] [BioSpace, April 2024]. The clinical and regulatory tailwind is also real. The FDA granted Breakthrough Device Designation and enrolled RESTORE in its Total Product Life Cycle Advisory Program pilot in April 2024, a signal that the agency sees a potentially important unmet-need category even if designation is not approval [Blue Arbor Technologies, April 2024] [BioSpace, April 2024]. Ottobock’s role as both strategic partner and investor points to another tailwind: large prosthetics incumbents appear willing to place targeted bets on control interfaces that could improve the utility of existing robotic hardware [ODT, February 2026] [Business Wire, October 2026].
The adjacent markets are arguably as important as the core one. Trade coverage suggests Blue Arbor’s underlying approach is relevant not only to upper-limb prosthetic control, but more broadly to human-machine interfaces where implanted sensing may outperform noninvasive signal capture [Medical Design & Outsourcing, June 2024]. That does not establish commercial traction in exoskeletons, rehabilitation robotics, or other assistive platforms, and the company has not publicly claimed those as launched markets. It does suggest that if the RESTORE architecture proves clinically durable, Blue Arbor could eventually compete for budget inside a wider assistive-robotics stack that includes sockets, hands, elbows, control software, rehabilitation services, and surgical implantation pathways [Medical Design & Outsourcing, June 2024] [Business Wire, October 2026].
Regulation is likely to shape this market more than headline demand does. Blue Arbor’s October 2026 financing announcement said proceeds would support U.S. clinical studies, feasibility work, and an FDA Investigational Device Exemption pathway, which indicates the market is still gated by trial design, evidence generation, and eventual reimbursement logic rather than by consumer pull alone [Business Wire, October 2026]. The first reported human procedures in Vienna are encouraging, but this remains a category where surgeon adoption, prosthetist workflow integration, long-term implant reliability, and payer acceptance will determine whether a promising device becomes a reimbursed standard of care or remains limited to specialized centers [Blue Arbor Technologies, February 2026] [Medical Design & Outsourcing, June 2024] [ODT, October 2026].
| Cited market signal | What it suggests for Blue Arbor | Source |
|---|---|---|
| Blue Arbor does not manufacture prostheses itself | The company is targeting the control layer within the prosthetics stack, not the full limb market | [Medical Design & Outsourcing, June 2024] |
| FDA Breakthrough Device Designation and TAP enrollment in April 2024 | Regulators see enough potential clinical relevance to support an accelerated engagement pathway | [Blue Arbor Technologies, April 2024] |
| Ottobock invested $5 million in February 2026 and led a $10.5 million Series A in October 2026 | Strategic incumbents in prosthetics are willing to fund this category before pivotal U.S. commercialization | [ODT, February 2026] [Business Wire, October 2026] |
| Proceeds are earmarked for U.S. clinical studies and IDE-related work | Category maturity is still evidence-led, with commercialization contingent on clinical and regulatory progress | [Business Wire, October 2026] |
The table is thin on absolute market size, but it captures the shape of the opportunity. Public evidence supports a real category need and credible strategic interest; it does not yet support a quantified market model for Blue Arbor’s exact wedge.
Lightly corroborated -- Section relies on named public sources and company announcements, but no independent third-party market-sizing report for Blue Arbor's exact category was surfaced.
Competitive Landscape
MIXED Blue Arbor is not competing head-on with a prosthetic-limb OEM so much as trying to become the control layer that makes advanced upper-limb prostheses meaningfully easier to use [Medical Design & Outsourcing, June 2024] [BioSpace, April 2024].
The public record supports a three-part map. Incumbents sit in prosthetic manufacturing and distribution, where Ottobock is the clearest named player in Blue Arbor's orbit because it is both the lead investor and a strategic partner, and because Blue Arbor's stated objective is to connect the peripheral nervous system to commercially available robotic prosthetics rather than build the limb itself [Blue Arbor Technologies, February 2026] [Business Wire, October 2026] [BioSpace, April 2024]. Challengers, as documented in the available materials, are harder to name company by company because the source set does not identify direct startup peers; what it does identify is an approach-level contest between implanted interfaces such as RESTORE and less invasive control methods, including surface-electrode systems that have historically mediated myoelectric prosthesis control [Medical Design & Outsourcing, June 2024]. Adjacent substitutes extend beyond prosthetic control itself, since Medical Design & Outsourcing reported potential future exoskeleton applications, which implies Blue Arbor's signal-decoding stack could eventually brush against other human-machine interface categories even if that is not the company's present commercial wedge [Medical Design & Outsourcing, June 2024].
Blue Arbor's edge today appears to rest less on sales reach than on technical depth, clinical positioning, and regulatory progress. The founding team's scientific base is unusually substantial for a company at this stage, with multiple public sources stating that the founders have collectively secured more than $60 million in direct research funding and produced more than 200 peer-reviewed publications [Today's Medical Developments, February 2026] [Pulse2, February 2026] [ODT, February 2026]. That matters because implantable prosthetic-control systems are not a category where product iteration can be separated from years of translational research. The FDA's Breakthrough Device Designation, plus enrollment in the Total Product Life Cycle Advisory Program pilot in April 2024, adds a second moat, though one that is better understood as an execution advantage than a permanent barrier, since it can narrow regulatory uncertainty without guaranteeing adoption or reimbursement [Blue Arbor Technologies, April 2024] [BioSpace, April 2024] [NS Medical Devices].
That edge is still perishable. Ottobock gives Blue Arbor a strategically relevant ally with obvious downstream importance in prosthetics, but the same fact also highlights the company's exposure: Blue Arbor does not appear to own the prosthetic limb, the patient relationship, or the clinic channel, at least from the public materials available here [Blue Arbor Technologies, February 2026] [Business Wire, October 2026] [Medical Design & Outsourcing, June 2024]. If commercially available prosthetic systems continue improving with non-implantable control methods, then the burden on Blue Arbor is not only to prove better signal fidelity, but to prove that the surgical and clinical workflow is justified. The strongest alternative named in the record is therefore not a startup peer but the incumbent stack around established prosthetic manufacturers, with Ottobock the clearest example, because those companies already control product distribution and clinician touchpoints even if Blue Arbor supplies the interface layer [Business Wire, October 2026] [Medical Design & Outsourcing, June 2024].
Over the next 18 months, the most plausible competitive scenario is a channel-led outcome rather than a brand-led one. Winner if X: Ottobock, if Blue Arbor's U.S. clinical preparation and feasibility work translate into evidence that implanted control materially improves function on commercially available robotic prosthetics, because Ottobock is already positioned as investor, strategic partner, and likely commercialization bridge [Business Wire, October 2026] [Blue Arbor Technologies, February 2026]. Loser if Y: Blue Arbor, if IDE-pathway work and human data advance more slowly than expected, or if the evidence gap between implanted and non-implantable control remains too narrow to change clinician behavior, because the company does not yet appear to control the incumbent distribution layer on its own [Business Wire, October 2026] [Medical Design & Outsourcing, June 2024]. The competitive question, then, is not whether upper-limb prosthetics need better control, but whether Blue Arbor can become the preferred control architecture before OEMs and established care channels settle around less invasive alternatives.
Lightly corroborated -- This section relies on two or more public sources for Blue Arbor's positioning, regulatory status, and Ottobock relationship, but direct named startup competitors are not identified in the provided source set, so parts of the competitive map remain approach-level rather than company-level.
Opportunity
Upside case
PUBLIC The prize here is unusually concentrated: if Blue Arbor can turn a hard neuromuscular-interface problem into a repeatable clinical product, it has a path to becoming a control layer that sits between patients with upper-limb loss and the advanced robotic prostheses already sold by incumbent manufacturers [BioSpace, April 2024] [Medical Design & Outsourcing, June 2024].
The headline opportunity is not that Blue Arbor becomes another prosthetics OEM. The more interesting outcome is that RESTORE becomes the enabling interface that makes high-end upper-limb prostheses materially more functional, and therefore more adoptable, without Blue Arbor having to manufacture the limb itself [Medical Design & Outsourcing, June 2024]. That is reachable, rather than purely aspirational, because three pieces are already in place in public sources: the company has an FDA Breakthrough Device Designation and TAP enrollment, which can matter in a novel medtech pathway [Blue Arbor Technologies, April 2024] [BioSpace, April 2024]; it has a named strategic investor in Ottobock, one of the best-known prosthetics companies globally [Blue Arbor Technologies, February 2026] [Business Wire, October 2026]; and it has reported first-in-human clinical work in Vienna, with later coverage indicating two implantations completed by October 2026 [Blue Arbor Technologies, February 2026] [ODT, October 2026]. For a company at this stage, that combination of regulatory signal, channel adjacency, and early human use is what makes the upside legible.
The public evidence supports more than one route to scale, but each route still depends on clinical proof translating into commercial adoption.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical wedge, then prosthetics standard | RESTORE proves superior control in upper-limb use cases and becomes a preferred interface for advanced robotic arms sold through established prosthetics channels | U.S. clinical studies and an FDA IDE pathway supported by the October 2026 Series A proceeds [Business Wire, October 2026] | Blue Arbor is already positioned as a control-system company rather than a limb manufacturer, and Ottobock is both investor and strategic partner [Medical Design & Outsourcing, June 2024] [Blue Arbor Technologies, February 2026] |
| Strategic platform inside incumbent ecosystems | Blue Arbor stays focused on the implanted interface and software stack while large OEMs and providers handle prosthetic distribution and patient access | Deeper product integration with a strategic investor that already operates in prosthetics [Blue Arbor Technologies, February 2026] [EQS News, February 2026] | Public materials repeatedly frame Ottobock as lead investor and strategic partner, which lowers the burden of building standalone distribution from scratch [Business Wire, October 2026] [ODT, February 2026] |
| Regulated neurotech expansion | The same implanted sensing and signal-translation architecture extends beyond prosthetic hands and arms into adjacent human-machine-control categories | Clinical feasibility work after the initial upper-limb indication [Business Wire, October 2026] | Trade coverage has described Blue Arbor's underlying approach as applicable to broader control contexts, including future exoskeleton applications, though that remains exploratory [Medical Design & Outsourcing, June 2024] |
What compounds, if this works, is not a consumer network effect but a clinical and ecosystem flywheel. One successful implantation program can generate surgeon familiarity, rehabilitation know-how, device-performance data, and tighter integration with prosthetic makers, all of which can make the next center easier to win and the next product iteration easier to justify [Business Wire, October 2026] [Medical Design & Outsourcing, June 2024]. The early signs of that flywheel are modest but visible: FDA Breakthrough Device Designation can improve engagement with regulators for novel devices, TAP enrollment can support earlier feedback, and Ottobock's role gives Blue Arbor a credible bridge into the installed prosthetics ecosystem rather than forcing a cold-start go-to-market motion [Blue Arbor Technologies, April 2024] [BioSpace, April 2024] [Blue Arbor Technologies, February 2026].
The size of the win is best understood as strategic value rather than a near-term revenue multiple. No public market comparable in the supplied sources gives a clean valuation anchor for implanted upper-limb neuromuscular interfaces, so any upside framing here has to stay conditional. If the "strategic platform inside incumbent ecosystems" scenario plays out, Blue Arbor could become a scarce acquisition or partnership asset for a major prosthetics player because it would control a differentiated interface layer, regulatory progress, and human clinical evidence in a category where improved control is central to product value (scenario, not a forecast) [Medical Design & Outsourcing, June 2024] [Business Wire, October 2026]. In plain terms, the company does not need to own the whole prosthetics stack to matter commercially. It needs to own the part that makes sophisticated hardware meaningfully better for patients.
Lightly corroborated -- Section relies on independent coverage from Business Wire, BioSpace, Medical Design & Outsourcing, ODT, and EQS News, but several core product-detail and clinical-progress claims remain partly company-sourced or single-source corroborated.
Sources
Public sources
[Blue Arbor Technologies, February 2026] Blue Arbor Technologies Announces Strategic Partnership with Ottobock and $5 Million Investment to Advance RESTORE™ Neuromuscular Interface System | https://bluearbortech.com/blue-arbor-technologies-announces-strategic-partnership-with-ottobock-and-5-million-investment-to-advance-restore-neuromuscular-interface-system/
[Business Wire, October 2026] Blue Arbor Technologies Raises $10.5 Million Series A Led by Ottobock | https://www.businesswire.com/news/home/20261028723707/en/
[Blue Arbor Technologies, April 2024] Blue Arbor Technologies Receives FDA Breakthrough Device Designation and TAP Enrollment for the RESTORE™ Neuromuscular Interface System | https://bluearbortech.com/blue-arbor-technologies-receives-fda-breakthrough-device-designation-and-tap-enrollment-for-the-restore-neuromuscular-interface-system/
[Crain’s Detroit Business, October 2026] UM spinout developing brain-controlled prosthetics nets $10.5M VC investment round. | https://www.crainsdetroit.com/technology/cdb-blue-arbor-series-a-105m-20261028/
[Behind the Microscope, February 2022] Paul Cederna, MD - Endless Opp… | https://podcasts.apple.com/us/podcast/paul-cederna-md-endless-opportunities-for-surgeon-scientists/id1484074780?i=1000550667081
[BioSpace, April 2024] Blue Arbor Technologies Receives FDA Breakthrough Device Designation and TAP Enrollment for the RESTORE™ Neuromuscular Interface System | https://www.biospace.com/blue-arbor-technologies-receives-fda-breakthrough-device-designation-and-tap-enrollment-for-the-restore-neuromuscular-interface-system
[Medical Design & Outsourcing, June 2024] Blue Arbor goes beneath the surface for better control of … | https://www.medicaldesignandoutsourcing.com/blue-arbor-limb-prosthetics-control-implants-exoskeleton/
[ODT, February 2026] Blue Arbor Technologies Nets $5M for Neuromuscular Interface System | https://www.odtmag.com/breaking-news/blue-arbor-technologies-nets-5-million-investment-for-neuromuscular-interface-system/
[Pulse2, February 2026] Blue Arbor Technologies: RESTORE Neuromuscular Interface System Company Raises $5 Million | https://pulse2.com/blue-arbor-technologies-restore-neuromuscular-interface-system-company-raises-5-million/
[PitchBook] Blue Arbor Technologies | https://pitchbook.com/profiles/company/blue-arbor-technologies
[Blue Arbor Technologies] Home | https://bluearbortech.com/
[Docwire News, February 2026] Blue Arbor Technologies Announces Strategic Partnership with Ottobock and $5 Million Investment to Advance RESTORE™ Neuromuscular Interface System | https://www.docwirenews.com/blue-arbor-technologies-announces-strategic-partnership-with-ottobock-and-5-million-investment-to-advance-restore-neuromuscular-interface-system/
[Today’s Medical Developments, February 2026] Blue Arbor Technologies announces strategic partnership with Ottobock and $5M investment | https://www.todaysmedicaldevelopments.com/news/blue-arbor-technologies-announces-strategic-partnership-with-ottobock-and-5m-investment/
[Medical Design & Outsourcing, February 2026] Blue Arbor, Ottobock partner on prosthetic control tech | https://www.medicaldesignandoutsourcing.com/blue-arbor-ottobock-prosthetic-control-tech/
[ODT, October 2026] Blue Arbor Technologies Raises $10.5M Series A Led by Ottobock | https://www.odtmag.com/breaking-news/blue-arbor-technologies-raises-10-5m-series-a-led-by-ottobock/
[EQS News, February 2026] Ottobock invests in future technology from Blue Arbor Technologies Inc. | https://www.eqs-news.com/news/corporate-news/ottobock-invests-in-future-technology-from-blue-arbor-technologies-inc/6b88f9a6-47e5-4e10-b975-79e1022e43fd_en
[NS Medical Devices] Blue Arbor Technologies secures FDA breakthrough tag for RESTORE system | https://www.nsmedicaldevices.com/news/blue-arbor-technologies-fda-breakthrough-restore-system/
Articles about Blue Arbor Technologies
- Blue Arbor's Implanted Electrodes Aim for a Natural Grip in Prosthetic Arms — The University of Michigan spinout, with strategic backing from prosthetic giant Ottobock, is advancing an implanted interface system that has already received FDA Breakthrough Device status.